<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Investigational biomarkers and the evaluation of acute kidney injury</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Investigational biomarkers and the evaluation of acute kidney injury</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Investigational biomarkers and the evaluation of acute kidney injury</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Uta Erdbruegger, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark D Okusa, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul M Palevsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H732288866"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) is a common clinical problem [<a href="#rid1">1-7</a>]. Although measurement of the serum creatinine concentration is widely used for the detection of AKI, it does not permit early diagnosis of acute tubular necrosis (ATN), since tubular injury precedes a significant rise in serum creatinine. Investigational biomarkers have been evaluated in patients with possible ATN in an attempt to detect tubular injury at an earlier stage. The US Food and Drug Administration (FDA) has approved use of the first platform measuring tissue inhibitor of metalloproteinases-2/insulin-like growth factor-binding protein 7 (TIMP-2/IGFBP7) to assess for the development of AKI. Other novel biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and liver-type fatty acid-binding protein (L-FABP) are approved in Europe and Japan, respectively.</p><p>We discuss here biomarkers that are being studied for the diagnosis of ATN. The pathophysiology, etiology, clinical presentation, and evaluation and diagnosis of prerenal disease and ATN are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults"</a>.)</p><p>The diagnostic approach to patients with acute or chronic kidney disease (CKD), the possible prevention and management of ATN, and kidney and patient outcomes after ATN are also discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7188.html" rel="external">"Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7224.html" rel="external">"Possible prevention and therapy of ischemic acute tubular necrosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7225.html" rel="external">"Kidney and patient outcomes after acute kidney injury in adults"</a>.)</p><p></p><p class="headingAnchor" id="H22961934"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The loss of kidney function in AKI is most easily detected by measurement of the serum creatinine, which is used to estimate the glomerular filtration rate (GFR). Although the serum creatinine is widely used in diagnosing the presence of AKI, it is a suboptimal biomarker. It is a lagging marker of change in kidney function; therefore, it has poor sensitivity for the early diagnosis of AKI, and, as a marker of glomerular filtration, it is unable to differentiate among the various causes of AKI [<a href="#rid8">8</a>]. As an example, the rise in serum creatinine is slow following the onset of AKI. By the time a change is observed in the serum creatinine, a critical therapeutic window may have been missed, particularly among those with ATN. A number of factors may contribute to a lag in rise of serum creatinine after AKI, including dilutional effect of fluid administration [<a href="#rid9">9</a>] and decrease in creatinine generation [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p>Thus, different urinary and serum proteins have been intensively investigated as possible biomarkers for the early diagnosis of ATN. There are promising candidate biomarkers that report on kidney and tubule function, detect an early and graded increase in tubular epithelial cell injury, and distinguish prerenal disease from ATN [<a href="#rid8">8,11-13</a>]. These novel biomarkers have the potential to reflect physiologic and pathophysiologic processes of the injured kidney. Some biomarkers are detected in the urine of patients without a diagnostic increase in serum creatinine, which defines a group of patients with "subclinical AKI" who are at risk for adverse outcomes [<a href="#rid14">14</a>]. Biomarkers are used in clinical investigation to facilitate early randomization to different treatment arms [<a href="#rid15">15</a>]. These vanguard studies using biomarkers may lead to the identification of new therapies and the practical use of biomarkers in routine patient care [<a href="#rid8">8,11,16-18</a>]. Future studies are also needed to investigate whether biomarker profiles reflect unique injuries and identify the site of injury. For instance, sepsis-associated AKI may have a biomarker profile that is distinctly different from that of nephrotoxin-associated AKI. The National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiated the Kidney Precision Medicine Project (KPMP). The objectives of KPMP are to ethically obtain human kidney biopsy samples from participants with AKI and chronic kidney disease (CKD), with a goal of identifying critical cells, pathways, and targets for therapy [<a href="#rid19">19</a>]. Tissue-driven definitions of AKI will permit identification of AKI subphenotypes that may be responsive to specific, targeted therapies. </p><p>Many candidate biomarkers have been identified. However, the following steps are necessary before they are used clinically:</p><p class="bulletIndent1"><span class="glyph">●</span>Validation in different settings of AKI (cardiac surgery, sepsis, contrast-induced nephropathy, emergency and pediatric medicine) and in different clinical centers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development and testing of rapid assays.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of a panel of tubular biomarkers that can be used in combination with clinical (eg, fluid overload) and/or functional biomarkers (eg, estimated GFR [eGFR] kinetics). It is unlikely that a single biomarker will suffice; rather, a panel of biomarkers will be necessary [<a href="#rid18">18</a>].</p><p></p><p>Additional barriers for implementing novel biomarkers exist [<a href="#rid20">20</a>]. For example, the optimal method of reporting biomarker excretion has not been determined. Urinary biomarker excretion may be reported as an absolute concentration or normalized to creatinine excretion. One study that compared these methods showed that the biomarker normalized to creatinine best predicted death, dialysis, or the development of AKI, although the absolute concentration best diagnosed AKI on admission [<a href="#rid21">21</a>]. </p><p class="headingAnchor" id="H732289043"><span class="h1">DIAGNOSTIC BIOMARKERS</span></p><p class="headingAnchor" id="H22961941"><span class="h2">Urinary tubular enzymes</span><span class="headingEndMark"> — </span>Urinary tubular enzymes consist of proximal renal tubular epithelial antigen (HRTE-1), alpha-glutathione S-transferase (alpha-GST), pi-glutathione S-transferase (pi-GST), gamma-glutamyltranspeptidase (gamma-GT), alanine aminopeptidase (AAP), lactate dehydrogenase (LDH), N-acetyl-beta-glucosaminidase (NAG), and alkaline phosphatase (ALP). Most of these are released from proximal tubular epithelial cells within 12 hours and four days earlier than a detectable rise in serum creatinine [<a href="#rid11">11,22</a>]. No validated cut-off points currently exist to help distinguish prerenal disease from ATN.</p><p class="headingAnchor" id="H22961948"><span class="h2">Urinary low-molecular-weight proteins</span><span class="headingEndMark"> — </span>Alpha1-microglobulin (alpha1-m), beta2-microglobulin (beta2-m), retinol-binding protein (RBP), adenosine deaminase-binding protein (ABP), and urinary cystatin C are urinary low-molecular-weight proteins. They are produced at different sites, filtered at the glomerulus, and reabsorbed at the proximal tubule with no secretion. Although promising prognostically and to help distinguish prerenal disease from ATN, increased levels may be observed after reversible and mild dysfunction and may not necessarily be associated with persistent or irreversible damage [<a href="#rid11">11,22,23</a>].</p><p class="headingAnchor" id="H22961955"><span class="h2">Neutrophil gelatinase-associated lipocalin (NGAL)</span><span class="headingEndMark"> — </span>NGAL is markedly upregulated and abundantly expressed in the kidney after kidney ischemia [<a href="#rid24">24</a>]. In this setting, NGAL may function to dampen toxicity by reducing apoptosis and increasing the normal proliferation of kidney tubule cells. In addition, by enhancing the delivery of iron, NGAL upregulates heme oxygenase-1, thereby helping protect kidney tubule cells [<a href="#rid24">24-28</a>]. NGAL is now approved for use as a biomarker of AKI in some countries. (See  <a class="medical medical_review" href="/z/d/html/7228.html" rel="external">"Pathogenesis and etiology of ischemic acute tubular necrosis"</a>.)</p><p>NGAL shows promise as a biomarker to help diagnose early ATN [<a href="#rid14">14,29-38</a>]. Furthermore, NGAL can differentiate prerenal disease from ATN. Using an NGAL reporter mouse, the NGAL-Luc2-mC reporter responds to endogenous signals that illuminate sites of injury (NGAL expression) in vivo and in real time. They found that, following ischemia reperfusion, as evidenced by a rise in creatinine, the kidneys illuminate, indicating NGAL production at the site of injury. Interestingly, following maneuvers that lead to significant prerenal disease associated with hypernatremia, there was no NGAL illumination, indicating that prerenal disease does not induce NGAL expression. Thus, NGAL may potentially be useful in differentiating prerenal disease from ATN [<a href="#rid39">39</a>].</p><p>NGAL has been tested in multiple studies of patients at risk for AKI due to sepsis, cardiac surgery, exposure to contrast media, or after kidney transplantation. In these studies, the average sensitivity and specificity of NGAL measured one to three days prior to AKI diagnosis was 76 and 77 percent, respectively, for cardiac surgery patients and 73 and 80 percent, respectively, for patients admitted to the intensive care unit (ICU) [<a href="#rid38">38</a>]. In a meta-analysis that examined the performance of a variety of novel AKI biomarkers in 110 studies with over 38,000 patients, biomarkers utilizing urinary and/or serum NGAL were the most accurate at predicting AKI [<a href="#rid40">40</a>].</p><p>Examples of specific studies are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary NGAL levels were determined in 196 children following cardiopulmonary bypass [<a href="#rid32">32</a>]. Ninety-nine patients sustained AKI, defined as a &gt;50 percent increase in serum creatinine. Urinary NGAL levels obtained at two hours following procedure correlated with severity and duration of AKI, length of stay, requirement for dialysis, and death.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary NGAL levels were determined in 635 consecutive patients assessed in the emergency department [<a href="#rid33">33</a>]. Thirty patients had AKI, defined as the new onset of a 50 percent increase in the serum creatinine level (compared with historic baseline) or a 25 percent decrease in estimated glomerular filtration rate (eGFR). The mean urinary NGAL level was significantly elevated in patients with AKI compared with those with normal kidney function, chronic kidney disease (CKD), or prerenal azotemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary NGAL among other biomarkers was measured in patients coming to the emergency department and at later time points in the ICU [<a href="#rid41">41</a>]. Urinary NGAL diagnosed AKI up to 48 hours. Testing later did not affect the AKI diagnostic performance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary NGAL, monomeric NGAL (mNGAL), interleukin (IL)-18, and other conventional urinary biomarkers for AKI (albumin, beta-2 microglobulin, fractional excretion of sodium) were measured at diagnosis and on days 3, 7, and 14 in 320 patients with AKI and decompensated cirrhosis. Among all biomarkers, urinary NGAL measured at day 3 had the greatest accuracy for differentiating ATN from all other types of AKI [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H22961962"><span class="h2">Urinary kidney injury molecule-1</span><span class="headingEndMark"> — </span>Kidney injury molecule-1 (KIM-1), also known as T cell immunoglobulin mucin domain-1 (TIM-1) [<a href="#rid43">43</a>], is a type 1 transmembrane glycoprotein that is low in normal kidneys but in high levels in the proximal tubule cells of kidneys with ischemic or toxic injury [<a href="#rid44">44,45</a>]. KIM-1 is a receptor for phosphatidylserine, an "eat-me" signal, expressed on cell surfaces of apoptotic cells that identifies them for removal by efferocytosis [<a href="#rid46">46</a>]. </p><p>The ectodomain of KIM-1 is a soluble fragment that can be measured in urine by immunoassay. KIM-1 has been tested in a number of cohorts serving as a sensitive and specific biomarker for AKI [<a href="#rid35">35,37,45,47,48</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study that included 123 adults undergoing cardiac surgery, urinary KIM-1, NGAL, cystatin C, hepatocyte growth factor, pi-GST, alpha-GST, and fractional excretion of sodium and urea were measured preoperatively, postoperatively, and at the time of the clinical diagnosis of AKI [<a href="#rid37">37</a>]. At various postoperative time points, cystatin C, NGAL, KIM-1, alpha-GST, and pi-GST all demonstrated ability to diagnose stage 3 AKI. Preoperative KIM-1 and alpha-GST predicted the development of stage 1 and stage 3 AKI, possibly reflecting subclinical proximal tubular injury present at this time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 38 patients, KIM-1 differentiated ATN from other forms of AKI and CKD [<a href="#rid45">45</a>]. The normalized urinary KIM-1 levels were significantly higher in patients with ischemic ATN (2.92) compared with levels in patients with other forms of AKI (0.63) or CKD (0.72). After adjustment for age, sex, time between the initial insult, and sampling of the urine, a one-unit increase in normalized KIM-1 was associated with a greater than 12-fold (odds ratio [OR] 12.4, 95% CI 1.2-119) risk for the presence of ATN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>KIM-1 was tested in a case-control study of 20 children who underwent cardiopulmonary bypass surgery both with and without complicating AKI [<a href="#rid48">48</a>]. Urinary KIM-1 was increased 6 to 12 hours following cardiopulmonary bypass and remained elevated up to 48 hours in patients who sustained a &gt;50 percent increase in serum creatinine within the first 48 hours but not in children who had normal kidney function. The increase in KIM-1 was paralleled by that of NGAL.</p><p></p><p class="headingAnchor" id="H22961969"><span class="h2">Urinary interleukin-18</span><span class="headingEndMark"> — </span>Urinary interleukin (IL)-18 has been shown to be elevated in patients with ATN compared with patients with prerenal azotemia, urinary tract infection (UTI), or CKD [<a href="#rid49">49-51</a>]. Its predictive utility for AKI following cardiac surgery could not be demonstrated in one prospective, observational study of 100 adult patients [<a href="#rid52">52</a>]. In addition, in a large study population of 1439 critically ill patients, IL-18 had a poor-to-moderate ability to predict AKI, kidney replacement therapy, or 90-day mortality [<a href="#rid53">53</a>]. Further studies are needed to clarify the role of urinary IL-18 as a biomarker.</p><p class="headingAnchor" id="H440297015"><span class="h2">Urinary liver-type fatty acid-binding protein in acute kidney injury</span><span class="headingEndMark"> — </span>Urinary excretion of urinary liver-type fatty acid-binding protein (L-FABP) reflects stress of proximal tubular epithelial cells and correlates with severity of ischemic tubular injury [<a href="#rid54">54</a>]. A meta-analysis of 15 prospective cohort studies demonstrated that, in hospital–based cohorts of patients at risk of AKI, L-FABP can discriminate for the diagnosis of AKI and predict the need for dialysis and in-hospital mortality [<a href="#rid55">55</a>]. Further validation is needed in large cohort studies.</p><p class="headingAnchor" id="H22961976"><span class="h2">Combination of biomarkers</span><span class="headingEndMark"> — </span>Several biomarkers are now investigated in panels [<a href="#rid35">35,56,57</a>], some including clinically available markers such as a urinary microscopy score [<a href="#rid58">58</a>]. In a prospective study of 90 adults with cardiac surgery, KIM-1, NAG, and NGAL were evaluated for early detection of AKI in the postoperative phase. The combined analysis of these three markers enhanced the sensitivity of early detection of postoperative AKI [<a href="#rid35">35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In another prospective, observational study, NGAL, cystatin C, and conventional markers like creatinine and urea were measured at different time points before and after cardiac surgery in 100 adult patients. NGAL and cystatin C (in patients with initial eGFR &gt;60 mL/min/1.73 m<sup>2</sup>) were independent predictors of AKI [<a href="#rid57">57</a>]. Similar findings were reported in another study of pediatric patients [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter, prospective, cohort study, five biomarkers were measured in 1635 unselected emergency department patients at time of hospital admission. Urinary NGAL and urinary KIM-1 predicted a composite outcome of dialysis initiation or death during hospitalization. These biomarkers could detect a subpopulation with low serum creatinine on admissions that was at risk of adverse events [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comparing five different biomarkers in a prospective, observational study of 529 patients in two ICUs, performance of biomarkers could be improved by stratification for time of collection with respect to kidney insult and for baseline kidney function before injury [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter, prospective cohort study of patients with cirrhosis and AKI, multiple biomarkers were used to assess the differential diagnosis of AKI [<a href="#rid62">62</a>]. Patients with ATN had significantly higher values of NGAL, IL-18, KIM-1, L-FABP, and albumin.</p><p></p><p>While new biomarkers are being validated, some older functional biomarkers (serum creatinine, serum urea, and urine output) continue to be utilized in the diagnosis and staging of AKI. In the future, the use of existing or newer damage biomarkers (eg, KIM-1) will likely be combined with the use of new and old functional biomarkers to enhance the ability of RIFLE, Acute Kidney Injury Network (AKIN), or Kidney Disease: Improving Global Outcomes (KDIGO) criteria to define AKI and to delineate a more precise AKI phenotype [<a href="#rid13">13,63</a>]. (See  <a class="medical medical_review" href="/z/d/html/7238.html" rel="external">"Definition and staging criteria of acute kidney injury in adults"</a>.) </p><p>These functional and damage biomarkers can also be tested along with other systemic and organ-specific biomarkers to assess the patient's AKI phenotype, which may then guide tailored therapeutic intervention.</p><p>Some investigators have studied the combination of biomarker data with clinical data to develop prediction models for AKI and other adverse outcomes. A three-variable model including age, cirrhosis, and soluble tumor necrosis factor (TNF) receptor-1 concentrations was tested in internal and external validation cohorts and had a high negative predictive value (0.94 to 0.95) for occurrence of severe AKI within 72 hours of ICU admission [<a href="#rid64">64</a>]. In another study, four distinct phenotypes of AKI were identified utilizing clinical data and biomarkers including KIM-1, NGAL, B-type natriuretic peptide (BNP), troponin T levels, uromodulin, and vascular inflammation markers (KL-40 and MCP-1). These AKI phenotypes were associated with longitudinal outcomes such as risk of CKD, cardiovascular events, and death [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H3530200757"><span class="h2">Other areas of research for biomarkers of AKI</span></p><p class="bulletIndent1"><span class="glyph">●</span>Proteomics – The role of protein profiling with laser mass spectrometry in urinary samples of patients with AKI is being investigated. This method allows identification of new and early markers of AKI [<a href="#rid66">66</a>]. In a derivation cohort of cardiac bypass surgery patients, a panel of 204 urinary peptides related to hemolysis, inflammation, immune cells, cell growth, and survival was identified as a potential predictor of AKI [<a href="#rid67">67</a>]. In two validation cohorts, this novel peptide signature outperformed several single biomarkers and clinical scores.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolomics – Metabolomics is the study of small-molecule metabolites that are produced by the body and provide insight into physiological and pathophysiological conditions. Metabolomic analysis can be readily performed in biofluids such as blood and urine, and, because there are fewer metabolites than there are genes, mRNA, and proteins, analyses are simpler. This method may allow for identification of new markers in AKI [<a href="#rid68">68,69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extracellular vesicles (EVs) – EVs are a heterogenous population of small submicron membrane fragments released from multivesicular bodies (exosomes, &lt;100 nm) or shed from various cell types into different body fluids (microvesicles, 100 to 1000 nm). They carry markers of their parent cells that are utilized to identify their origin. In particular, urinary EVs contain proteins from various nephron segments providing nephron-specific information [<a href="#rid70">70</a>]. In addition, EVs represent an important mode of intercellular communication by serving as vehicles for transfer between cells of membrane and cytosolic proteins, lipids, and genetic information. Therefore, these EVs have important implications with regard to biomarkers and mechanisms of disease [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MicroRNAs – Serum microRNAs are being explored in patients with AKI [<a href="#rid72">72</a>]. MicroRNAs were profiled in 77 patients with AKI and 18 critically ill patients with acute myocardial infarction [<a href="#rid73">73</a>]. Circulating microRNAs were altered in patients with AKI. MicroRNA-210 predicted mortality in this patient cohort.</p><p></p><p class="bulletIndent1">Other pilot studies are indicating other sets of microRNAs to be altered days before increase in serum creatinine [<a href="#rid74">74,75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Markers of inflammation – Plasma IL-6 and IL-10 have been measured in adults undergoing cardiac surgery. IL-6 and IL-10 were elevated after surgery and associated with higher risk for AKI [<a href="#rid76">76</a>]. In a substudy of the Translational Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI) cohort, plasma IL-6 and IL-10 were measured in 106 children undergoing cardiopulmonary bypass. Preoperative plasma IL-6 concentrations were associated with the development of stage 2 and 3 AKI [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Others – Additional novel markers that have been evaluated include serum cystatin C levels, isoform 3 of the sodium-hydrogen exchanger (NHE3), perforin and granzyme B, CXCR3-binding chemokines, endothelin, ProANP (1Y 98), tryptophan glycoconjugate and cysteine-rich protein 61 (CYR61), fatty acid-binding protein, TNF receptor-I, plasminogen activator inhibitor-1, netrin-1 [<a href="#rid78">78</a>], activating transcription factor 3 (ATF3), and MCP-1 [<a href="#rid8">8,11,79-82</a>]. Prospective studies need to be done to evaluate the utility of these biomarkers.</p><p></p><p class="headingAnchor" id="H732289067"><span class="h1">PROGNOSTIC BIOMARKERS</span><span class="headingEndMark"> — </span>Most of the biomarkers described above allow early detection of AKI but do not predict severe AKI.</p><p class="headingAnchor" id="H853769603"><span class="h2">Soluble urokinase plasminogen activator receptor (suPAR)</span><span class="headingEndMark"> — </span>suPAR is the circulating form of the membrane-bound uPAR, a glycosyl-phosphatidylinositol-anchored protein normally expressed on endothelial cells, podocytes, and, with induced expression, on monocytes and lymphocytes [<a href="#rid83">83,84</a>]. It can be measured in plasma using commercially available assays. In the setting of inflammation, uPAR is shed by immune cells following proteolytic cleavage and travels as the soluble form, suPAR. suPAR is thought to represent a biomarker of immune activation and inflammation [<a href="#rid85">85</a>]. suPAR is thought to interact with cells in the kidney (eg, podocytes, glomerular cells, and tubular epithelial cells) to trigger mitochondrial superoxide generation and a heightened energy demand, ultimately leading to kidney injury [<a href="#rid86">86-89</a>].</p><p>As a biomarker, suPAR was predictive of progressive decline in kidney function in a number of studies that included healthy participants and patients with CKD of various etiologies [<a href="#rid86">86,90-94</a>]. Systemic levels of suPAR have also been shown to correlate with markers of organ dysfunction and may enable prognostication in critically ill patients [<a href="#rid85">85</a>].</p><p>suPAR was also predictive of AKI in multiple cohorts [<a href="#rid87">87,95,96</a>]. In one study, for example, high levels of suPAR were associated with risk of mild to moderate AKI within the first seven days after cardiac surgery, coronary angiography, or ICU admission [<a href="#rid87">87</a>]. However, the relationship of suPAR with AKI is confounded by its association with conditions such as infection, sepsis, cardiovascular disease, diabetes, cancer, and liver failure, which themselves are risk factors for AKI [<a href="#rid85">85,88</a>]. </p><p class="headingAnchor" id="H2110692216"><span class="h2">Dickkopf-3</span><span class="headingEndMark"> — </span>The preoperative urinary concentration of dickkopf-3 (DKK3), a urinary cytokine and tubular stress biomarker, has been used to identify surgical patients at high risk for AKI [<a href="#rid97">97</a>]. In over 700 patients who were scheduled to undergo cardiac surgery, elevated urinary DKK3 to creatinine ratios were associated with an increased risk of postoperative AKI, independent of baseline kidney function. Furthermore, compared with clinical and other laboratory data, urinary DKK3 to creatinine ratios improved AKI prediction. </p><p class="headingAnchor" id="H2394070231"><span class="h2">Uromodulin (Tamm-Horsfall protein)</span><span class="headingEndMark"> — </span>Uromodulin is a 95-kD glycoprotein produced by the thick ascending limb and the distal convoluted tubule [<a href="#rid98">98</a>] and is thought to bind pathogenic bacteria and prevent stone formation [<a href="#rid99">99,100</a>]. Mice deficient of uromodulin are more susceptible to ischemia-reperfusion kidney injury [<a href="#rid101">101</a>]. In a post-hoc analysis of a prospective cohort study of 218 adult patients undergoing cardiac surgery, lower urinary uromodulin/creatinine ratio was associated with higher odds for AKI [<a href="#rid102">102</a>]. In children undergoing cardiopulmonary bypass surgery, preoperative urinary uromodulin also has been assessed as a predictive biomarker [<a href="#rid103">103</a>]. Children in the lowest quartile of urinary uromodulin levels had a markedly increased risk of postoperative AKI compared with those in the highest quartile.</p><p class="headingAnchor" id="H117878942"><span class="h2">Plasma NGAL</span><span class="headingEndMark"> — </span>In a prospective, cohort study in which 616 patients admitted from the emergency department were classified by clinical criteria as AKI, transient azotemia, stable chronic kidney disease (CKD), or normal kidney function, plasma NGAL discriminated AKI from normal function and from transient azotemia [<a href="#rid104">104</a>]. Higher concentrations of NGAL were associated with more severe AKI.</p><p class="headingAnchor" id="H1333944"><span class="h2">Urinary insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP2)</span><span class="headingEndMark"> — </span>Sepsis- and ischemia-induced cell injury and repair are associated with cell cycle regulation [<a href="#rid105">105,106</a>]. IGFBP7 and TIMP-2, two urinary biomarkers identified in a discovery study, are expressed in epithelial cells and act in an autocrine and paracrine manner to arrest cell cycle in AKI.</p><p>In the Sapphire validation study of over 700 critically ill patients, the primary endpoint was moderate to severe AKI (Kidney Disease: Improving Global Outcomes [KDIGO] stage 2 to 3) within 12 hours of sample collection. These markers performed well in patients with sepsis (with area under the receiver operating characteristics curve [AUC] of 0.82) and postsurgery (AUC 0.85) in comparison with traditional biomarkers and improved risk stratification for AKI well ahead of clinical manifestations (azotemia and oliguria) [<a href="#rid107">107</a>]. An analysis of the Sapphire validation study showed that the use of TIMP-2/IGFBP7 identified patients at risk for death or dialysis during the ensuing nine months after study enrollment.</p><p>A point-of-care device measuring those two biomarkers was approved by the US Food and Drug Administration (FDA) in 2014, though defining the appropriate timing and frequency of biomarker measurement and interpreting these results in individual patients remains the focus of future studies [<a href="#rid108">108</a>]. The positive predictive value to diagnose CKD stages 2 and 3 (ie, estimated glomerular filtration rate [eGFR] 30 to 89 mL/min/1.73 m<sup>2</sup>) was 49 percent, and the negative predictive value was 97 percent [<a href="#rid109">109,110</a>]. The clinical value of this point-of-care device is being assessed in different clinical settings of AKI [<a href="#rid111">111</a>]. (See  <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults", section on 'GFR'</a>.)</p><p>Two randomized trials have utilized postoperative urinary TIMP-2/IGFBP7 values to identify patients at high risk of AKI after cardiac surgery [<a href="#rid112">112,113</a>].</p><p class="headingAnchor" id="H1576393794"><span class="h2">Furosemide stress test</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> stress test (FST) was developed as a clinical tool to assess the risk for AKI progression [<a href="#rid114">114</a>]. FST entails administration of intravenous furosemide (1 mg/kg in furosemide-naïve and 1.5 mg/kg in non-naïve) to euvolemic patients with stage 1 or 2 AKI. A urine output of &gt;200 mL over two hours after administration of furosemide indicates FST responsiveness. In observational studies, FST-unresponsiveness was predictive of progression to stage 3 AKI, need for kidney replacement therapy, and higher inpatient mortality [<a href="#rid114">114-117</a>]. </p><p class="headingAnchor" id="H985398586"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational biomarkers of acute kidney injury</strong> – Acute kidney injury (AKI) is a common clinical problem. Although measurement of the serum creatinine concentration is widely used for the detection of AKI, it does not permit early diagnosis of acute tubular necrosis (ATN), since tubular injury precedes a significant rise in serum creatinine. Investigational biomarkers have been evaluated in patients with possible ATN in an attempt to detect tubular injury at an earlier stage. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steps necessary for clinical use</strong> – Various urinary and serum proteins have been intensively investigated as possible biomarkers for the early diagnosis of ATN. Before any such proteins are used clinically, validation in different settings of AKI and the development and testing of rapid assays are necessary. In addition, it needs to be shown if there is an association between levels of biomarkers and outcome. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic biomarkers</strong> – Promising biomarkers for the diagnosis of AKI include neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), urinary interleukin (IL)-18, and liver-type fatty acid-binding protein (L-FABP), among others. (See <a class="local">'Diagnostic biomarkers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic biomarkers</strong> – The development of biomarkers that predict the occurrence and/or severity of AKI would allow for personalized interventions to prevent or minimize AKI. Assays proposed to identify patients at high risk of AKI, such as the product of urinary insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2), are the focus of ongoing studies. (See <a class="local">'Prognostic biomarkers'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120:c179.</a></li><li><a class="nounderline abstract_t">Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365:417.</a></li><li><a class="nounderline abstract_t">Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. Kidney Int 2007; 72:208.</a></li><li><a class="nounderline abstract_t">Waikar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17:1143.</a></li><li><a class="nounderline abstract_t">Xue JL, Daniels F, Star RA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006; 17:1135.</a></li><li><a class="nounderline abstract_t">Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294:813.</a></li><li><a class="nounderline abstract_t">Liangos O, Wald R, O'Bell JW, et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006; 1:43.</a></li><li><a class="nounderline abstract_t">Bonventre JV. Diagnosis of acute kidney injury: from classic parameters to new biomarkers. Contrib Nephrol 2007; 156:213.</a></li><li><a class="nounderline abstract_t">Macedo E, Bouchard J, Soroko SH, et al. Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. Crit Care 2010; 14:R82.</a></li><li><a class="nounderline abstract_t">Pickering JW, Ralib AM, Endre ZH. Combining creatinine and volume kinetics identifies missed cases of acute kidney injury following cardiac arrest. Crit Care 2013; 17:R7.</a></li><li><a class="nounderline abstract_t">Trof RJ, Di Maggio F, Leemreis J, Groeneveld AB. Biomarkers of acute renal injury and renal failure. Shock 2006; 26:245.</a></li><li><a class="nounderline abstract_t">Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant 2013; 28:254.</a></li><li><a class="nounderline abstract_t">Charlton JR, Portilla D, Okusa MD. A basic science view of acute kidney injury biomarkers. Nephrol Dial Transplant 2014; 29:1301.</a></li><li><a class="nounderline abstract_t">Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011; 57:1752.</a></li><li><a class="nounderline abstract_t">Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77:1020.</a></li><li><a class="nounderline abstract_t">Bagshaw SM, Langenberg C, Haase M, et al. Urinary biomarkers in septic acute kidney injury. Intensive Care Med 2007; 33:1285.</a></li><li><a class="nounderline abstract_t">Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol 2007; 156:203.</a></li><li><a class="nounderline abstract_t">Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol 2008; 23:2151.</a></li><li class="breakAll">National Institutes of Diabetes and Digestive and Kidney Diseases: Kidney Precision Medicine Project (KPMP), 2016. https://www.niddk.nih.gov/research-funding/research-programs/Documents/KPMP_Diagram_508.pdf. (Accessed on September 30, 2016).</li><li><a class="nounderline abstract_t">Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw Open 2020; 3:e2019209.</a></li><li><a class="nounderline abstract_t">Ralib AM, Pickering JW, Shaw GM, et al. Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J Am Soc Nephrol 2012; 23:322.</a></li><li><a class="nounderline abstract_t">Herget-Rosenthal S, Poppen D, Hüsing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50:552.</a></li><li><a class="nounderline abstract_t">Uchida K, Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002; 323:121.</a></li><li><a class="nounderline abstract_t">Herget-Rosenthal S. One step forward in the early detection of acute renal failure. Lancet 2005; 365:1205.</a></li><li><a class="nounderline abstract_t">Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268:10425.</a></li><li><a class="nounderline abstract_t">Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14:2534.</a></li><li><a class="nounderline abstract_t">Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004; 15:3073.</a></li><li><a class="nounderline abstract_t">Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115:610.</a></li><li><a class="nounderline abstract_t">Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365:1231.</a></li><li><a class="nounderline abstract_t">Wagener G, Jan M, Kim M, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006; 105:485.</a></li><li><a class="nounderline abstract_t">Zappitelli M, Washburn KK, Arikan AA, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007; 11:R84.</a></li><li><a class="nounderline abstract_t">Bennett M, Dent CL, Ma Q, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008; 3:665.</a></li><li><a class="nounderline abstract_t">Nickolas TL, O'Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008; 148:810.</a></li><li><a class="nounderline abstract_t">Wagener G, Gubitosa G, Wang S, et al. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis 2008; 52:425.</a></li><li><a class="nounderline abstract_t">Han WK, Wagener G, Zhu Y, et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4:873.</a></li><li><a class="nounderline abstract_t">Siew ED, Ware LB, Gebretsadik T, et al. Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J Am Soc Nephrol 2009; 20:1823.</a></li><li><a class="nounderline abstract_t">Koyner JL, Vaidya VS, Bennett MR, et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010; 5:2154.</a></li><li><a class="nounderline abstract_t">Haase M, Haase-Fielitz A, Bellomo R, Mertens PR. Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease. Curr Opin Hematol 2011; 18:11.</a></li><li><a class="nounderline abstract_t">Paragas N, Qiu A, Zhang Q, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011; 17:216.</a></li><li><a class="nounderline abstract_t">Pan HC, Yang SY, Chiou TT, et al. Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: a systematic review and meta-analysis. Crit Care 2022; 26:349.</a></li><li><a class="nounderline abstract_t">Ralib AM, Pickering JW, Shaw GM, et al. The clinical utility window for acute kidney injury biomarkers in the critically ill. Crit Care 2014; 18:601.</a></li><li><a class="nounderline abstract_t">Huelin P, Solà E, Elia C, et al. Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology 2019; 70:319.</a></li><li><a class="nounderline abstract_t">McIntire JJ, Umetsu SE, Akbari O, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001; 2:1109.</a></li><li><a class="nounderline abstract_t">Vaidya VS, Ramirez V, Ichimura T, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006; 290:F517.</a></li><li><a class="nounderline abstract_t">Han WK, Bailly V, Abichandani R, et al. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62:237.</a></li><li><a class="nounderline abstract_t">Morioka S, Maueröder C, Ravichandran KS. Living on the Edge: Efferocytosis at the Interface of Homeostasis and Pathology. Immunity 2019; 50:1149.</a></li><li><a class="nounderline abstract_t">Steiner RW. Interpreting the fractional excretion of sodium. Am J Med 1984; 77:699.</a></li><li><a class="nounderline abstract_t">Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73:863.</a></li><li><a class="nounderline abstract_t">Zhou H, Hewitt SM, Yuen PS, Star RA. Acute Kidney Injury Biomarkers - Needs, Present Status, and Future Promise. Nephrol Self Assess Program 2006; 5:63.</a></li><li><a class="nounderline abstract_t">Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006; 70:199.</a></li><li><a class="nounderline abstract_t">Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005; 16:3046.</a></li><li><a class="nounderline abstract_t">Haase M, Bellomo R, Story D, et al. Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study. Crit Care 2008; 12:R96.</a></li><li><a class="nounderline abstract_t">Nisula S, Yang R, Poukkanen M, et al. Predictive value of urine interleukin-18 in the evolution and outcome of acute kidney injury in critically ill adult patients. Br J Anaesth 2015; 114:460.</a></li><li><a class="nounderline abstract_t">Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004; 165:1243.</a></li><li><a class="nounderline abstract_t">Susantitaphong P, Siribamrungwong M, Doi K, et al. Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis. Am J Kidney Dis 2013; 61:430.</a></li><li><a class="nounderline abstract_t">Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009; 14:423.</a></li><li><a class="nounderline abstract_t">Haase-Fielitz A, Bellomo R, Devarajan P, et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study. Crit Care Med 2009; 37:553.</a></li><li><a class="nounderline abstract_t">Hall IE, Coca SG, Perazella MA, et al. Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis. Clin J Am Soc Nephrol 2011; 6:2740.</a></li><li><a class="nounderline abstract_t">Basu RK, Wong HR, Krawczeski CD, et al. Combining functional and tubular damage biomarkers improves diagnostic precision for acute kidney injury after cardiac surgery. J Am Coll Cardiol 2014; 64:2753.</a></li><li><a class="nounderline abstract_t">Nickolas TL, Schmidt-Ott KM, Canetta P, et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol 2012; 59:246.</a></li><li><a class="nounderline abstract_t">Endre ZH, Pickering JW, Walker RJ, et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int 2011; 79:1119.</a></li><li><a class="nounderline abstract_t">Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014; 60:622.</a></li><li><a class="nounderline abstract_t">McCullough PA, Shaw AD, Haase M, et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol 2013; 182:13.</a></li><li><a class="nounderline abstract_t">Bhatraju PK, Zelnick LR, Katz R, et al. A Prediction Model for Severe AKI in Critically Ill Adults That Incorporates Clinical and Biomarker Data. Clin J Am Soc Nephrol 2019; 14:506.</a></li><li><a class="nounderline abstract_t">Vasquez-Rios G, Oh W, Lee S, et al. Joint Modeling of Clinical and Biomarker Data in Acute Kidney Injury Defines Unique Subphenotypes with Differing Outcomes. Clin J Am Soc Nephrol 2023; 18:716.</a></li><li><a class="nounderline abstract_t">Ho J, Lucy M, Krokhin O, et al. Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study. Am J Kidney Dis 2009; 53:584.</a></li><li><a class="nounderline abstract_t">Piedrafita A, Siwy J, Klein J, et al. A universal predictive and mechanistic urinary peptide signature in acute kidney injury. Crit Care 2022; 26:344.</a></li><li><a class="nounderline abstract_t">Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol 2011; 8:22.</a></li><li><a class="nounderline abstract_t">Wei Q, Xiao X, Fogle P, Dong Z. Changes in metabolic profiles during acute kidney injury and recovery following ischemia/reperfusion. PLoS One 2014; 9:e106647.</a></li><li><a class="nounderline abstract_t">Erdbrügger U, Le TH. Extracellular Vesicles in Renal Diseases: More than Novel Biomarkers? J Am Soc Nephrol 2016; 27:12.</a></li><li><a class="nounderline abstract_t">Yavuz H, Weder MM, Erdbrügger U. Extracellular Vesicles in Acute Kidney Injury. Nephron 2023; 147:48.</a></li><li><a class="nounderline abstract_t">Liu Z, Wang Y, Shu S, et al. Non-coding RNAs in kidney injury and repair. Am J Physiol Cell Physiol 2019; 317:C177.</a></li><li><a class="nounderline abstract_t">Lorenzen JM, Kielstein JT, Hafer C, et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2011; 6:1540.</a></li><li><a class="nounderline abstract_t">Aguado-Fraile E, Ramos E, Conde E, et al. A Pilot Study Identifying a Set of microRNAs As Precise Diagnostic Biomarkers of Acute Kidney Injury. PLoS One 2015; 10:e0127175.</a></li><li><a class="nounderline abstract_t">Mahtal N, Lenoir O, Tinel C, et al. MicroRNAs in kidney injury and disease. Nat Rev Nephrol 2022; 18:643.</a></li><li><a class="nounderline abstract_t">Zhang WR, Garg AX, Coca SG, et al. Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. J Am Soc Nephrol 2015; 26:3123.</a></li><li><a class="nounderline abstract_t">Greenberg JH, Whitlock R, Zhang WR, et al. Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. Pediatr Nephrol 2015; 30:1519.</a></li><li><a class="nounderline abstract_t">Ramesh G, Krawczeski CD, Woo JG, et al. Urinary netrin-1 is an early predictive biomarker of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2010; 5:395.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol 2007; 18:2894.</a></li><li><a class="nounderline abstract_t">Liu KD, Glidden DV, Eisner MD, et al. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Crit Care Med 2007; 35:2755.</a></li><li><a class="nounderline abstract_t">Zhou H, Cheruvanky A, Hu X, et al. Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int 2008; 74:613.</a></li><li><a class="nounderline abstract_t">Munshi R, Johnson A, Siew ED, et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol 2011; 22:165.</a></li><li><a class="nounderline abstract_t">Wei C, Möller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14:55.</a></li><li><a class="nounderline abstract_t">Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311:656.</a></li><li><a class="nounderline abstract_t">Backes Y, van der Sluijs KF, Mackie DP, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 2012; 38:1418.</a></li><li><a class="nounderline abstract_t">Hahm E, Wei C, Fernandez I, et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med 2017; 23:100.</a></li><li><a class="nounderline abstract_t">Hayek SS, Leaf DE, Samman Tahhan A, et al. Soluble Urokinase Receptor and Acute Kidney Injury. N Engl J Med 2020; 382:416.</a></li><li><a class="nounderline abstract_t">Tacke F. Risk Prediction for Acute Kidney Injury - Super Important, Now suPAR Easy? N Engl J Med 2020; 382:470.</a></li><li><a class="nounderline abstract_t">Hayek SS, Sever S, Ko YA, et al. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med 2015; 373:1916.</a></li><li><a class="nounderline abstract_t">Hayek SS, Ko YA, Awad M, et al. Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study. Kidney Int Rep 2017; 2:425.</a></li><li><a class="nounderline abstract_t">Luo S, Coresh J, Tin A, et al. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Clin J Am Soc Nephrol 2018; 13:1013.</a></li><li><a class="nounderline abstract_t">Schaefer F, Trachtman H, Wühl E, et al. Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. JAMA Pediatr 2017; 171:e172914.</a></li><li><a class="nounderline abstract_t">Schulz CA, Persson M, Christensson A, et al. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study. Kidney Int Rep 2017; 2:239.</a></li><li><a class="nounderline abstract_t">Hayek SS, Landsittel DP, Wei C, et al. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 2019; 30:1305.</a></li><li><a class="nounderline abstract_t">Mossanen JC, Pracht J, Jansen TU, et al. Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery. Int J Mol Sci 2017; 18.</a></li><li><a class="nounderline abstract_t">Nusshag C, Rupp C, Schmitt F, et al. Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study. Crit Care Med 2019; 47:e999.</a></li><li><a class="nounderline abstract_t">Schunk SJ, Zarbock A, Meersch M, et al. Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study. Lancet 2019; 394:488.</a></li><li><a class="nounderline abstract_t">Lhotta K. Uromodulin and chronic kidney disease. Kidney Blood Press Res 2010; 33:393.</a></li><li><a class="nounderline abstract_t">Glauser A, Hochreiter W, Jaeger P, Hess B. Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 2000; 15:1580.</a></li><li><a class="nounderline abstract_t">Pak J, Pu Y, Zhang ZT, et al. Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 2001; 276:9924.</a></li><li><a class="nounderline abstract_t">El-Achkar TM, Wu XR, Rauchman M, et al. Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Renal Physiol 2008; 295:F534.</a></li><li><a class="nounderline abstract_t">Garimella PS, Jaber BL, Tighiouart H, et al. Association of Preoperative Urinary Uromodulin with AKI after Cardiac Surgery. Clin J Am Soc Nephrol 2017; 12:10.</a></li><li><a class="nounderline abstract_t">Bennett MR, Pyles O, Ma Q, Devarajan P. Preoperative levels of urinary uromodulin predict acute kidney injury after pediatric cardiopulmonary bypass surgery. Pediatr Nephrol 2018; 33:521.</a></li><li><a class="nounderline abstract_t">Soto K, Papoila AL, Coelho S, et al. Plasma NGAL for the diagnosis of AKI in patients admitted from the emergency department setting. Clin J Am Soc Nephrol 2013; 8:2053.</a></li><li><a class="nounderline abstract_t">Witzgall R, Brown D, Schwarz C, Bonventre JV. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 1994; 93:2175.</a></li><li><a class="nounderline abstract_t">Yang QH, Liu DW, Long Y, et al. Acute renal failure during sepsis: potential role of cell cycle regulation. J Infect 2009; 58:459.</a></li><li><a class="nounderline abstract_t">Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013; 17:R25.</a></li><li><a class="nounderline abstract_t">Koyner JL, Shaw AD, Chawla LS, et al. Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI. J Am Soc Nephrol 2015; 26:1747.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2:1.</a></li><li><a class="nounderline abstract_t">Bihorac A, Chawla LS, Shaw AD, et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 2014; 189:932.</a></li><li><a class="nounderline abstract_t">Fan W, Ankawi G, Zhang J, et al. Current understanding and future directions in the application of TIMP-2 and IGFBP7 in AKI clinical practice. Clin Chem Lab Med 2019; 57:567.</a></li><li><a class="nounderline abstract_t">Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med 2017; 43:1551.</a></li><li><a class="nounderline abstract_t">Zarbock A, Küllmar M, Ostermann M, et al. Prevention of Cardiac Surgery-Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial. Anesth Analg 2021; 133:292.</a></li><li><a class="nounderline abstract_t">Chawla LS, Davison DL, Brasha-Mitchell E, et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care 2013; 17:R207.</a></li><li><a class="nounderline abstract_t">Lumlertgul N, Peerapornratana S, Trakarnvanich T, et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). Crit Care 2018; 22:101.</a></li><li><a class="nounderline abstract_t">Rewa OG, Bagshaw SM, Wang X, et al. The furosemide stress test for prediction of worsening acute kidney injury in critically ill patients: A multicenter, prospective, observational study. J Crit Care 2019; 52:109.</a></li><li><a class="nounderline abstract_t">Koyner JL, Davison DL, Brasha-Mitchell E, et al. Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity. J Am Soc Nephrol 2015; 26:2023.</a></li></ol></div><div id="topicVersionRevision">Topic 85837 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890468" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : KDIGO clinical practice guidelines for acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15680458" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17507907" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Community-based incidence of acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495376" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Declining mortality in patients with acute renal failure, 1988 to 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495381" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16106006" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acute renal failure in critically ill patients: a multinational, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699189" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17464130" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis of acute kidney injury: from classic parameters to new biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20459609" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23327106" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Combining creatinine and volume kinetics identifies missed cases of acute kidney injury following cardiac arrest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912649" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Biomarkers of acute renal injury and renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23115326" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24385545" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A basic science view of acute kidney injury biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511111" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164823" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17487471" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Urinary biomarkers in septic acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17464129" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Emerging biomarkers of acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17394022" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Biomarkers for the early detection of acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17394022" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Biomarkers for the early detection of acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33021646" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22095948" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14709451" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12135813" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Measurement of cystatin-C and creatinine in urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15811437" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : One step forward in the early detection of acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7683678" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514731" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579510" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15711640" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15811456" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931980" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17678545" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337554" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519927" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18649981" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406962" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628673" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20798258" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21102325" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21240264" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Ngal reporter mouse detects the response of the kidney to injury in real time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36371256" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25366893" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The clinical utility window for acute kidney injury biomarkers in the critically ill.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30810244" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11725301" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174863" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081583" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31117011" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Living on the Edge: Efferocytosis at the Interface of Homeostasis and Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486145" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Interpreting the fractional excretion of sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18059454" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Urinary biomarkers in the early diagnosis of acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19096722" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute Kidney Injury Biomarkers - Needs, Present Status, and Future Promise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16710348" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148039" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18673539" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25472925" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Predictive value of urine interleukin-18 in the evolution and outcome of acute kidney injury in critically ill adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466390" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23228945" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19572801" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114878" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22034509" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25541128" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Combining functional and tubular damage biomarkers improves diagnostic precision for acute kidney injury after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22240130" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307838" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24375576" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23689653" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30917991" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A Prediction Model for Severe AKI in Critically Ill Adults That Incorporates Clinical and Biomarker Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36975209" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Joint Modeling of Clinical and Biomarker Data in Acute Kidney Injury Defines Unique Subphenotypes with Differing Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19070948" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36345008" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A universal predictive and mechanistic urinary peptide signature in acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025087" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Metabolomics in the study of kidney diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25191961" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Changes in metabolic profiles during acute kidney injury and recovery following ischemia/reperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26251351" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Extracellular Vesicles in Renal Diseases: More than Novel Biomarkers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36183697" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Extracellular Vesicles in Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30969781" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Non-coding RNAs in kidney injury and repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700819" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Circulating miR-210 predicts survival in critically ill patients with acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26079930" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A Pilot Study Identifying a Set of microRNAs As Precise Diagnostic Biomarkers of Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35974169" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : MicroRNAs in kidney injury and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25855775" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25877915" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20007677" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Urinary netrin-1 is an early predictive biomarker of acute kidney injury after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942962" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Renal L-type fatty acid--binding protein in acute ischemic injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18074478" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18509321" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Urinary exosomal transcription factors, a new class of biomarkers for renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21071523" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : MCP-1 gene activation marks acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18084301" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Modification of kidney barrier function by the urokinase receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16456079" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Structure of human urokinase plasminogen activator in complex with its receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22706919" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941791" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31995687" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Soluble Urokinase Receptor and Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31995696" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Risk Prediction for Acute Kidney Injury - Super Important, Now suPAR Easy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26539835" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Soluble Urokinase Receptor and Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29142970" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29903900" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28873129" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28367534" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based MalmöDiet and Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31171572" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28758975" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31584458" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31202596" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20948228" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Uromodulin and chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007825" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134021" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18495803" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27797887" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Association of Preoperative Urinary Uromodulin with AKI after Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29058155" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Preoperative levels of urinary uromodulin predict acute kidney injury after pediatric cardiopulmonary bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24009223" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Plasma NGAL for the diagnosis of AKI in patients admitted from the emergency department setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910173" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19428114" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Acute renal failure during sepsis: potential role of cell cycle regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388612" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25535301" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : KDIGO Clinical Practice Guideline for Acute Kidney Injury</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24559465" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30179848" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Current understanding and future directions in the application of TIMP-2 and IGFBP7 in AKI clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110412" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33684086" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Prevention of Cardiac Surgery-Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24053972" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Development and standardization of a furosemide stress test to predict the severity of acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29673370" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31035185" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The furosemide stress test for prediction of worsening acute kidney injury in critically ill patients: A multicenter, prospective, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25655065" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
